Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Titel:
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Auteur:
Robak, Tadeusz Kaźmierczak, Maciej Jarque, Isidro Musteata, Vasile Treliński, Jacek Cooper, Nichola Kiessling, Peter Massow, Ute Woltering, Franz Snipes, Rose Ke, Juan Langdon, Grant Bussel, James B. Jolles, Stephen